Cancer Biomarkers - Volume 15, issue 2

Authors: Ghanbari, Reza | Mosakhani, Neda | Asadi, Jahanbakhsh | Nouraee, Nazila | Mowla, Seyed Javad | Poustchi, Hossein} | Malekzadeh, Reza | Knuutila, Sakari

Article Type: Research Article

Abstract: Background: Colorectal cancer (CRC) is a major cause of cancer-related deaths world-wide. Detection of molecular markers in stool samples is a promising strategy for CRC screening. MicroRNAs (miRNAs) are short, non-coding RNA molecules that are commonly dysregulated in neoplasia. Objective: The objective of this study was to evaluate the fecal miRNAs differentiation between early-stage CRC patients and healthy subjects. Methods: Stool samples were collected from 40 patients with early stage (I, II) CRC and 16 healthy controls. RNA was extracted from all samples using miRNAeasy Mini Kits. MiRNA microarray expression profiling was performed with Agilent’s miRNA …Microarray system on 12 CRC and 8 normal stool samples. The expression levels of miR-4478 and miR-1295b-3p were determined by the SYBR Green miScript PCR system. Results: In profiling study, we found 215 down-regulated miRNAs in CRC group. Furthermore, in validation study we found that the expression levels of fecal miR-4487 and miR-1295b-3p were significantly decreased in CRC patients compared to healthy controls. Conclusions: The expression of miR-4478 and miR-1295b-3p were significantly diminished in stool samples of CRC patients with early stage (I, II) in comparison with normal group. These miRNAs maybe use as potential non-invasive molecular markers for CRC diagnosis, but further studies are needed. Show more

Keywords: Profiling, microarray, diagnosis

DOI: 10.3233/CBM-140453

Citation: Cancer Biomarkers, vol. 15, no. 2, pp. 189-195, 2015

Authors: Mhaidat, Nizar M. | Alzoubi, Karem H. | Almomani, Nabeela | Khabour, Omar F.

Article Type: Research Article

Abstract: Background: Colorectal cancer (CRC) is an important health problem all over the world. A great improvement in the screening and early detection of CRC has been achieved. However, a new molecular prognostic marker is largely required. Glucose regulated protein 78-kDa (GRP78) is the central regulator of the endoplasmic reticulum (ER) and has an important role in the proliferation, differentiation and resistance to chemotherapy in cancer cells. Objective: The aim of the present study was to investigate the impact of elevated level of GRP78 on CRC prognosis and chemosensitivity. Methods: Sixty eight CRC tissue samples were collected …and protein expression of GRP78 was evaluated using immunohistochemistry. The clinicopathological factors of the patients were correlated with GRP78 level. Results: GRP78 expression increased with the progression from early to advanced CRC stages. In addition, GRP78 level was increased with the progression from early T1-2 to late T3-4 tumor localization (p< 0.05). Moreover, a significant association was found between GRP78 expression and response to chemotherapy (p< 0.05). Association between GRP78 expression and patient’s clinical characteristics including lymph node involvement and metastasis was not significant. Conclusions: Results suggest the possibility to use GRP78 as a biomarker for progression of CRC and its chemosensitivity to therapy. Show more

Keywords: Colorectal cancer, GRP78, Chemotherapy, Apoptosis

DOI: 10.3233/CBM-140454

Citation: Cancer Biomarkers, vol. 15, no. 2, pp. 197-203, 2015

Authors: Yang, Jie | Yang, Fan | Nie, Jiqin | Zou, Xiaohua | Tian, Huiqun | Qin, Yu'e | Liu, Chaoqi

Article Type: Research Article

Abstract: Annexin A2 (ANXA2) is a 36 kDa protein which orchestrates multiple biologic processes and clinical associations, especially in cancer progression. It is important to establish a specific and sensitive ANXA2 enzyme-linked immunosorbent assay (ELISA) for the study of ANXA2 functions and its clinical application. Therefore, we prepared a polyclonal antibody (PAb) in rabbits and a monoclonal antibody (MAb) in mices immunized with a recombinant ANXA2 protein. Based on our self-made MAb and PAb, highly specific and sensitive ELISA was developed. The detection limitation of ANXA2 was 10 ng/mL and the linear dynamic range was between 10 and 500 ng/mL. Using …the established ELISA, we detected ANXA2 protein in human serum. It was found that soluble ANXA2 concentration in serum samples from 42 lung cancer patients was significantly higher than that from 43 healthy individuals (p< 0.01). Our data provides a new approach for detecting soluble ANXA2, especially in large ongoing and future clinical studies. Show more

Keywords: Annexin A2, serum biomarker, lung cancer, ELISA

DOI: 10.3233/CBM-140455

Citation: Cancer Biomarkers, vol. 15, no. 2, pp. 205-211, 2015